A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
Eric S. Lightcap(Minneapolis Business College), Dennis Huszar(Millennium Engineering and Integration (United States)), Beryl A. Hatton(Presage Biosciences (United States)), Pengfei Yu(University of Illinois Urbana-Champaign), Hisashi Imaichi(AVEO Oncology (United States)), James Minissale(Takeda (United States)), Erik Koenig(Millennium Engineering and Integration (United States)), Katherine Galvin(Takeda (United States)), Vaishali Shinde(AVEO Oncology (United States)), Stephen Grossman(Takeda (United States)), Mithun Khattar(AVEO Oncology (United States)), Michael A. Milhollen(Millennium Engineering and Integration (United States)), Yu Fu(AVEO Oncology (United States)), Richard A. Klinghoffer(Tempus Labs (United States)), Steven Langston(Millennium Engineering and Integration (United States)), James M. Gavin(Millennium Engineering and Integration (United States)), Xingyue He(Changchun University of Chinese Medicine), Jessica Riceberg(Takeda (United States)), James Garnsey(Millennium Engineering and Integration (United States)), Dylan B. England(Takeda (United States)), Zhen Lu(Shanghai Zhangjiang Laboratory), Kristina Xega(Takeda (United States)), Cong Li(The Affiliated Yongchuan Hospital of Chongqing Medical University), Xiaofeng Yang(Millennium Engineering and Integration (United States)), Hongru Zhang(Third Affiliated Hospital of Zhengzhou University), Pooja Shah(Takeda (United States)), Sai Murali Krishna Pulukuri(Takeda (United States)), Gary Shapiro(AVEO Oncology (United States)), Keli Song(Takeda (United States)), Serge Y. Fuchs(University of Pennsylvania)
Cited by 139
Related Papers
Src family kinases are required for integrin but not PDGFR signal transduction
|The EMBO Journal|1999|729